In preclinical studies, orally available FLT3/CDK4 dual kinase inhibitor AMG-925 (Figure 5) showed efficacy in AML tumor models and inhibited signaling in sorafenib-resistant AML cell lines [78]. The gene discussed is CDK4; the disease is acute myeloid leukemia.